retatrutide triple agonist glp-1 gip glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept Retatrutide vs Tirzepatide 🔬 What's

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus

The absence of a control group precludes definitive conclusions on causality between GLP-1 receptor agonist therapy and observed outcomes, and residual confounding cannot be excluded In conclusion, arGLP-1 represent a valuable addition to the therapeutic arsenal for managing IWL or WR after BS

A global price disparity for GLP-1 drugs The US pays far more than peer nations for the same medicationsup to 10x higherhighlighting the nations fractured pharmaceutical pricing structure and raising questions about equitable access

Its important to understand that these medications manage a chronic condition, not provide a quick fix

Oral formulations and forthcoming biosimilars are essential to unlocking second- and third-tier city penetration across the region